EGFR and non-small cell lung carcinoma: Existing evidence supports that in individuals with common EGFR mutations and NSCLC, 2nd generation TKIs (afatinib or dacomitinib) are associated with improved PFS compared to the 1st generation TKI gefitinib [9, 10].